TECHNICAL NOTE

Advancing pharmacogenomics with NGS and CNV analysis

Routine pharmacogenomic (PGx) testing has significant potential to improve drug efficacy and safety.

This Technical Note explores key considerations for PGx analysis, with a focus on the advantages of copy number variation (CNV) detection and next-generation sequencing (NGS) over traditional methodologies.

We introduce the SOPHiA DDM™ Community Pharmacogenomics Solution, expertly designed for rapid and accurate identification of PGx-related variants, enhancing precision medicine through advanced analytics.

Read Technical Note

First Name

Last Name

Institution

Job Title

Area of Interest

Country

State

Privacy Policy I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. View our Privacy Policy for more information.

Pardot Opt-in I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able to unsubscribe by using the link integrated with the communication at any time.

Comments